Zealand Pharma AS ZEAL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
-
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
-
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
-
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
-
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
-
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
-
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
-
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
Trading Information
- Previous Close Price
- DKK 232.00
- Day Range
- DKK 229.70–233.80
- 52-Week Range
- DKK 220.60–556.00
- Bid/Ask
- DKK 232.80 / DKK 233.00
- Shares Outstanding
- 66.33M
- Market Cap
- DKK 15.44B
- Volume/Avg
- 78,541 / 374,578
Key Statistics
- Price/Earnings (Normalized)
- 6.35
- Price/Sales
- 3.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.53%
Company Profile
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 578
- Website
- https://www.zealandpharma.com
Valuation
|
Metric
|
ZEAL
|
|---|---|
Price/Earnings (Normalized) | 6.35 |
Price/Book Value | 0.89 |
Price/Sales | 3.55 |
Price/Cash Flow | 9.67 |
Price/Earnings
ZEAL
Financial Strength
|
Metric
|
ZEAL
|
|---|---|
Quick Ratio | 13.76 |
Current Ratio | 13.98 |
Interest Coverage | 92.71 |
Quick Ratio
ZEAL
Profitability
|
Metric
|
ZEAL
|
|---|---|
Return on Assets (Normalized) | 17.40% |
Return on Equity (Normalized) | 18.94% |
Return on Invested Capital (Normalized) | 16.47% |
Return on Assets
ZEAL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SVmq@< | LOCK|g!<@y | $137B | |||
| Moderna Inc
MRNA
| LOCK|&V>^FG& | LOCK|ss | $89B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sSgXDX | LOCK|D>W%z | $84B | |||
| argenx SE ADR
ARGX
| LOCK|Xb#>GNG | LOCK|??$ | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|c&#cl%f | LOCK|??X | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|xX>H<y#S | LOCK|^&!Nb | $29B | |||
| Incyte Corp
INCY
| LOCK|j$>C^!% | LOCK|^$% | $24B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|HkGn?%? | LOCK|!^q@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^rXyPGv | LOCK|%lD | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|f%^w<x# | LOCK|<R | $14B |
United States